Calithera Biosciences Inc (CALA)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
The rising entity from the Major Pharmaceutical Preparations sector the Calithera Biosciences Inc issued the fiscal fourth quarter of 2022, results
company reported fourth quarter of 2022 operating loss of $-7.346 million
Published Apr 02 2023
Goran Soko / CSIMarket.com Contributer
![pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/Dryvax_pd.jpg "pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
The shareholders haven't expected some modifications at the revenue all over the October to December 31 2022 reporting cycle at the CALA. However, they pay close attention to the company's operating loss that came in at $-7.346 million, in the same period. Currently, it is conspicuous that, the ascending entity did conduct business more cost-effective, then in the comparable period a prior year. Coming from operating loss of $-69.209 million.
All over the fourth quarter of 2022 earnings season, the Executives have ran the CALA much more cost-effective and cut the diminishing Returns to $-5.574 million.
CALA announced loss of $-21.29 million and revenue of $0.00 million in the financial year 2022.
Net loss per share has widen to $-7.94 from $-1.56 in the prior financial year, while by 0 % from $9.75 million a year prior.
Calithera Biosciences Inc is expected to report next financial recent numbers on May 09, 2023.